- Home
- Publications
- Publication Search
- Publication Details
Title
The emerging role of complement in neuromuscular disorders
Authors
Keywords
-
Journal
Seminars in Immunopathology
Volume 43, Issue 6, Pages 817-828
Publisher
Springer Science and Business Media LLC
Online
2021-10-27
DOI
10.1007/s00281-021-00895-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dynamic regulation of B cell complement signaling is integral to germinal center responses
- (2021) Arun Cumpelik et al. NATURE IMMUNOLOGY
- Changes in serum complements and their regulators in generalized myasthenia gravis
- (2020) Y. Ozawa et al. EUROPEAN JOURNAL OF NEUROLOGY
- Complement in neurological disorders and emerging complement-targeted therapeutics
- (2020) Marinos C. Dalakas et al. Nature Reviews Neurology
- Myasthenia gravis
- (2019) Nils Erik Gilhus et al. Nature Reviews Disease Primers
- Revisiting the role of the innate immune complement system in ALS
- (2019) Sandra E. Parker et al. NEUROBIOLOGY OF DISEASE
- Muscular dystrophies
- (2019) Eugenio Mercuri et al. LANCET
- Complement dysregulation in the central nervous system during development and disease
- (2019) John D. Lee et al. SEMINARS IN IMMUNOLOGY
- Serological and experimental studies in different forms of myasthenia gravis
- (2018) Angela Vincent et al. Annals of the New York Academy of Sciences
- Eculizumab: A Review in Generalized Myasthenia Gravis
- (2018) Sohita Dhillon DRUGS
- Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis
- (2018) John D. Lee et al. Journal of Neuroinflammation
- Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis
- (2018) Anne-Lene Kjældgaard et al. MOLECULAR IMMUNOLOGY
- Eculizumab: a treatment option for myasthenia gravis?
- (2017) Nils Erik Gilhus LANCET NEUROLOGY
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- (2017) James F Howard et al. LANCET NEUROLOGY
- Amyotrophic Lateral Sclerosis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis
- (2017) Haitao A. Wang et al. Skeletal Muscle
- Amyotrophic lateral sclerosis
- (2017) Orla Hardiman et al. Nature Reviews Disease Primers
- Complement-Mediated Regulation of Metabolism and Basic Cellular Processes
- (2016) Christoph Hess et al. IMMUNITY
- Complement activation at the motor end-plates in amyotrophic lateral sclerosis
- (2016) Nawal Bahia El Idrissi et al. Journal of Neuroinflammation
- Complement in disease: a defence system turning offensive
- (2016) Daniel Ricklin et al. Nature Reviews Nephrology
- Myasthenia gravis — autoantibody characteristics and their implications for therapy
- (2016) Nils Erik Gilhus et al. Nature Reviews Neurology
- Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization
- (2015) Erdem Tuzun et al. EXPERIMENTAL NEUROLOGY
- Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors — Recommendations for methods and experimental designs
- (2015) Mario Losen et al. EXPERIMENTAL NEUROLOGY
- Corrections
- (2015) LANCET NEUROLOGY
- Myasthenia gravis: subgroup classification and therapeutic strategies
- (2015) Nils Erik Gilhus et al. LANCET NEUROLOGY
- Immune-mediated pathology in Duchenne muscular dystrophy
- (2015) Amy S. Rosenberg et al. Science Translational Medicine
- Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood
- (2014) S. Mantovani et al. JOURNAL OF NEUROIMMUNOLOGY
- LRP4 Is Critical for Neuromuscular Junction Maintenance
- (2014) A. Barik et al. JOURNAL OF NEUROSCIENCE
- Genetic Variants in C5 and Poor Response to Eculizumab
- (2014) Jun-ichi Nishimura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role for terminal complement activation in amyotrophic lateral sclerosis disease progression
- (2014) T. M. Woodruff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Complement associated pathogenic mechanisms in myasthenia gravis
- (2013) Erdem Tüzün et al. AUTOIMMUNITY REVIEWS
- Complement C2 siRNA mediated therapy of myasthenia gravis in mice
- (2013) Ruksana Huda et al. JOURNAL OF AUTOIMMUNITY
- Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis
- (2013) John D Lee et al. Journal of Neuroinflammation
- Innate Immunity and Neuroinflammation
- (2013) Abhishek Shastri et al. MEDIATORS OF INFLAMMATION
- A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
- (2013) James F. Howard et al. MUSCLE & NERVE
- Targeting therapy to the neuromuscular junction: Proof of concept
- (2013) Linda L. Kusner et al. MUSCLE & NERVE
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
- (2013) C.M. Legendre et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assembly and Regulation of the Membrane Attack Complex Based on Structures of C5b6 and sC5b9
- (2012) Michael A. Hadders et al. Cell Reports
- Acetylcholine Receptor-Induced Experimental Myasthenia Gravis: What Have We Learned from Animal Models After Three Decades?
- (2011) Fulvio Baggi et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis
- (2011) Bianca Heurich et al. JOURNAL OF NEUROIMMUNOLOGY
- Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation
- (2011) M. Sta et al. NEUROBIOLOGY OF DISEASE
- Current and emerging therapies for the treatment of myasthenia gravis
- (2011) Renato Mantegazza Neuropsychiatric Disease and Treatment
- Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice
- (2010) Renzhi Han et al. JOURNAL OF CLINICAL INVESTIGATION
- Distinct localization of collagen Q and PRiMA forms of acetylcholinesterase at the neuromuscular junction
- (2010) Véronique Bernard et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Complement: a key system for immune surveillance and homeostasis
- (2010) Daniel Ricklin et al. NATURE IMMUNOLOGY
- Novel complement inhibitor limits severity of experimentally myasthenia gravis
- (2009) Jindrich Soltys et al. ANNALS OF NEUROLOGY
- Complement component 5a (C5a)
- (2009) Helga D. Manthey et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis
- (2009) Jing Li et al. JOURNAL OF NEUROIMMUNOLOGY
- C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis
- (2008) H QI et al. JOURNAL OF NEUROIMMUNOLOGY
- Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo
- (2007) Natalie J. Hepburn et al. MOLECULAR IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started